New Delhi, India – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of 1000 active Cath lab (interventional suite) installations in India. Over the last quarter, the company has installed its state-of-the-art Azurion cath labs at major sites across the country including Fortis, Apollo, Aster, Manipal, NH and Jayadeva Institute of Cardiovascular Sciences and Research Hospitals. The completion of 1000 active cath lab installations mark a major milestone in Philips’ mission to create innovative solutions designed to meet the company’s Quadruple Aim of better health outcomes, improved patient experience, improved staff experience, and lower cost of care.
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities. Philips has been a trusted partner for the Indian healthcare community for over two decades, having pioneered the treatment of cardiovascular diseases through innovative minimally invasive procedures. Currently, the company’s cath labs are present in all major tertiary care, Government and Private hospitals across India.